hit counter

Resistance Exercise Linked to Lower Depression and Anxiety in Korean Adults

A 2026 nationwide Korean analysis found that resistance exercise was associated with lower depression and anxiety scores after propensity score matching, while aerobic exercise alone was not significantly associated with either outcome. The result favors adding weights, bands, machines, or body-weight strength work to mental-health exercise advice without assuming that lifting caused the lower symptom …

Read more

Suicide in Sculpture: Public Art Makes Risk Socially Visible

MHD featured image for suicide-themed sculpture, public art, psychache, and prevention.

A 2026 qualitative analysis treated suicide-themed sculpture as cultural evidence, showing how public artworks can materialize psychological pain, shame, entrapment, social disconnection, and prevention debates without turning artists or viewers into diagnostic case studies.1 Research Highlights 2026 analysis used cultural methods: the researchers used iconographic, semiotic, and contextual analysis rather than clinical diagnosis or outcome …

Read more

TRD MRI Coupling Classified Depression Resistance Above 0.88 AUC

A 2026 multimodal MRI study found that treatment-resistant depression had lower coordination between brain structure and brain activity than non-treatment-resistant depression in frontal, parietal, motor, and temporal regions. Machine-learning models using those structure-function coupling measures classified treatment-resistant vs. non-treatment-resistant depression with AUC values from 0.886 to 0.950 in the primary atlas analysis.1 Research Highlights TRD …

Read more

Naltrexone Reduced Reappraisal Distress in 38-Person Threat fMRI Trial

Photoreal illustration of brain with vmPFC, amygdala, and threat-processing circuitry highlighted under pharmacological challenge.

The endogenous opioid system has been a candidate target for novel anxiety treatments, but a 2026 placebo-controlled crossover fMRI study in 38 healthy volunteers ran opposite the hypothesis: instead of increasing threat-related distress and amygdala reactivity, 50 mg oral naltrexone reduced subjective distress during cognitive reappraisal (p = 0.044, d = 0.57) and shifted ventromedial …

Read more

Esketamine Failed Cost-Effectiveness vs. Cheaper TRD Options at $50K/QALY

Photoreal illustration of a depression-treatment decision with cost and outcome imagery, conveying healthcare-economic decision-making.

Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …

Read more

SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission

MHD featured image for SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission.

A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …

Read more